Coordinating Biotechnology Oversight: Streamlining Regulation for Safety and Innovation.
This Act establishes an interagency committee to coordinate and streamline federal oversight of biotechnology products (plants, animals, microorganisms). The goal is to protect public health and the environment while accelerating the safe development and commercialization of innovations. Citizens benefit from increased transparency regarding regulatory timelines and processes, which will be publicly reported.
Key points
Creation of the Biotechnology Oversight Coordination Committee, involving key agencies (e.g., FDA, EPA, USDA), to eliminate regulatory duplication and delays.
Mandate to align regulatory timelines and data requirements to speed up the review process for new biotechnology products.
Requirement to develop a single, unified, and publicly available process for assessing whether a biotech product could have occurred naturally.
Exclusion of human medical research and products regulated solely by the Food and Drug Administration (FDA) from the scope of the Act.
Expired
Citizen Poll